Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SEVERFIELD PLC AGM Information 2019

Sep 3, 2019

4741_dva_2019-09-03_cdb0d50d-3427-440b-9dff-cfb0892768a0.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0924L

Severfield PLC

03 September 2019

SEVERFIELD PLC

Results of Annual General Meeting 2019

At the Company's Annual General Meeting held at 12 noon today, 3 September, all of the resolutions were passed on a show of hands.

Copies of all the resolutions passed have been submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for review at http://www.hemscott.com/nsm.do.

A summary of Proxies received in respect of each resolution is set out below (a "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of the votes for and against the resolution):

In Favour Against Total Withheld
Resolution No of   votes % of votes No of votes % of votes No of   votes No of votes
1.   To receive and adopt the annual accounts and the reports of the Directors for the financial year ended 31 March 2019 together with the report of the auditors thereon. 243,594,241 100.00 6,061 0.00 243,600,302 23,615
2.   To approve the Directors' remuneration report (other than the part containing the Directors' remuneration policy) for the financial year ended 31 March 2019 as set out in the Annual Report and Accounts 2019. 241,737,371 99.89 254,417 0.11 241,991,788 1,632,127
3.   To declare a final dividend of 1.8p per ordinary share in respect of the year ended 31 March 2019 payable on 13th September 2019 to shareholders on the register at the close of business on 16th August 2019. 243,623,917 100.00 0 0.00 243,623,917 0
4.   To reappoint John Dodds as a Director. 240,727,997 98.83 2,861,787 1.17 243,589,784 34,132
5.   To reappoint Ian Cochrane as a Director. 243,572,077 99.99 17,708 0.01 243,589,785 34,132
6.   To reappoint Alan Dunsmore as a Director. 242,044,479 100.00 11,526 0.00 242,056,005 1,567,911
7.   To reappoint Derek Randall as a Director. 243,576,535 99.99 13,250 0.01 243,589,785 34,132
8.   To reappoint Adam Semple as a Director. 243,548,076 99.98 41,709 0.02 243,589,785 34,132
9.   To reappoint Alun Griffiths as a Director. 243,503,628 99.96 86,157 0.04 243,589,785 34,132
10.  To reappoint Tony Osbaldiston as a Director. 243,508,628 99.97 81,157 0.03 243,589,785 34,132
11.  To reappoint Kevin Whiteman as a Director. 243,509,552 99.97 78,733 0.03 243,588,285 35,632
12.  To reappoint KPMG LLP as auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company in 2020. 241,876,455 99.33 1,641,208 0.67 243,517,663 106,254
13.  To authorise the Directors to determine the auditors' remuneration. 241,978,838 99.34 1,614,759 0.66 243,593,597 30,320
14.  To authorise the Directors to allot securities of the Company. 243,370,393 99.90 250,728 0.10 243,621,121 2,796
15.  To authorise the Directors to dis-apply pre-emption rights in relation to the issue of securities of the Company. 243,341,187 99.89 265,976 0.11 243,607,163 16,754
16.  To authorise the Directors to dis-apply pre-emption rights in connection with an acquisition or specified capital investment. 241,787,622 99.26 1,805,710 0.74 243,593,332 30,584
17.  To authorise the Company to make market purchases of the Company's ordinary shares. 241,801,663 99.28 1,762,405 0.72 243,564,068 59,848
18.  That a general meeting of the Company (other than an annual general meeting) may be called on not less than 14 clear days' notice. 242,298,748 99.46 1,306,669 0.54 243,605,417 18,500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGZMGGLDFLGLZM